Follow-up During the Peripubertal Period of Preterm Children Included in the Protocol Entitled "EPIPOD".
NCT ID: NCT04945369
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
114 participants
INTERVENTIONAL
2022-02-02
2028-02-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It has been demonstrated that the body composition of children born prematurely is different from that of children born under term with a deficit in fat free mass.
It can thus be wondered if this excessive adiposity does or does not predict the risk of insulin resistance in adulthood.
Children born prematurely, with a body composition measurement performed at discharge from neonatal hospitalization as part of the EPIPOD protocol, and now aged between 8 and 14 years, will be included in the INFANTPOD protocol.
Analysis of body composition, insulin resistance, renal function, pulse wave velocity, eating behaviour and of physical activity will be performed.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Children born prematurely included in the EPIPOD protocol and now in the peripubertal period
At inclusion in the INFANTPOD study :
* Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.
* Assessment of body composition by a commercialized device called "BOP-POD" and by impedancemetry
* Assessment of pulse wave by a commercialized device called "popmetre"
* Questionnaires for analysis of eating behaviour
* Assessment of physical activity by a commercialized device called "accelerometer" and by questionnaire.
clinical and biological measurements and questionnaires
Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.
Assessment of body composition by BOP-POD and by impedancemetry. Assessment of pulse wave by popmetre. Assessment of physical activity by accelerometer and by questionnaire Questionnaires for analysis of eating behaviour
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
clinical and biological measurements and questionnaires
Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.
Assessment of body composition by BOP-POD and by impedancemetry. Assessment of pulse wave by popmetre. Assessment of physical activity by accelerometer and by questionnaire Questionnaires for analysis of eating behaviour
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With a body composition measurement performed at discharge from neonatal hospitalization as part of the EPIPOD protocol
* Born prematurely (under 35 weeks of amenorrhea)
* Included in the Lift cohort with follow-up up to 7 years
* Aged between 8 and 14 years at inclusion
Exclusion Criteria
* Age of 15 years or more
* with a chromosomal anomaly
* with contraindicating measurement of the BOP-POD: ventilatory support, continuous parenteral feeding, elimination stoma
* Refusal of either parent or child
8 Years
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nantes University Hospital
Nantes, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anne FRONDAS, Doctor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC20_0522
Identifier Type: -
Identifier Source: org_study_id